A shocking discovery has turned conventional wisdom on its head: a cellular enzyme, once hailed as a protector against fatty liver disease, may actually be hiding a sinister secret – increasing the risk of liver cancer as we age.
This revelation comes from a groundbreaking study published in Science Advances, spearheaded by researchers at Adelaide University. They've found that the absence of the enzyme Caspase-2 can trigger a cascade of events leading to chronic liver damage and, ultimately, a higher chance of developing liver cancer. But here's where it gets controversial: Caspase-2 inhibitors have been gaining traction as a potential treatment for fatty liver disease. This research throws a wrench in those plans, urging caution when considering this approach.
So, what's the deal with Caspase-2? According to lead researcher Dr. Loretta Dorstyn, it's a critical player in maintaining the genetic integrity of liver cells, while also helping to regulate fat levels. "Liver cells normally have extra copies of genetic material – known as polyploidy – and while this feature can help the liver cope with stress, our study shows that without the enzyme Caspase-2, abnormally high levels of polyploidy in the liver can be damaging," she explained.
To understand this better, the researchers used genetically modified mice. They found that mice lacking Caspase-2, or with a non-functional version, experienced abnormal liver cell growth, significant genetic and cellular damage, chronic inflammation, and scarring – mirroring hepatitis-like liver disease. And the kicker? These mice were significantly more likely to develop liver cancer as they aged, with up to four times the incidence of hepatocellular carcinoma.
Dr. Dorstyn further clarifies that while inhibiting Caspase-2 might seem beneficial in the short term, especially in young animals, its long-term absence is clearly detrimental. "Our study demonstrates that Caspase-2 is essential for removing damaged and abnormal liver cells as we age. Without it, these cells accumulate and can become cancerous, while also creating an environment that predisposes the liver to cancer."
Professor Sharad Kumar, the senior author, emphasizes the implications for drug development: "Our data shows that this approach could have serious unintended consequences later in life, increasing susceptibility to chronic liver inflammation, fibrosis, and cancer."
This research is particularly timely given the rising global burden of liver disease, fueled by an aging population, obesity, and metabolic disorders. Liver cancer claimed nearly 760,000 lives worldwide in 2022, making it the 6th most common cancer globally, according to the World Cancer Research Fund.
This study, 'Caspase-2 deficiency drives pathogenic liver polyploidy and increases age- associated hepatocellular carcinoma in mice' (DOI: 10.1126/sciadv.aeb2571), challenges us to rethink our strategies for treating fatty liver disease.
What do you think? Are you surprised by these findings? Do you believe this will change the approach to treating fatty liver disease? Share your thoughts in the comments below!
